clinical trial

AB0032 ASSESSMENT OF AUTONOMIC DYSFUNCTION AND ITS RELATIONS WITH CLINICAL PARAMETERS IN FAMILIAL MEDITERRANEAN FEVER (FMF)
I. Kalkan, M. T. Duruöz

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1241-1242; DOI: 10.1136/annrheumdis-2024-eular.4894
AB0051 THE ASSOCIATION BETWEEN COVID-19 INFECTION AND DISEASE FLARES IN PATIENTS WITH BEHÇET’S SYNDROME
W. Zheng, Y. Liu, Z. Wang, X. Yu, J. Liu

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1252-1253; DOI: 10.1136/annrheumdis-2024-eular.1909
AB0050 COULD WE HAVE A NEW WAY TO MEASURE DISEASE ACTIVITY IN BEHÇET’S DISEASE
Y. Hussein, Y. Sadeq, S. Mashaly

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1252; DOI: 10.1136/annrheumdis-2024-eular.1083
AB0066 UNRAVELING KEY FACTORS IN COVID-19 VACCINATION AMONG RHEUMATOID ARTHRITIS PATIENTS: A LANDMARK MONOCENTRIC INVESTIGATION
H. Elhani, H. Toufik, L. Taoubane, N. EL Ouardi, A. Majjad, A. Bezza

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1262; DOI: 10.1136/annrheumdis-2024-eular.4598
POS0466 OBEXELIMAB INHIBITS BCR SIGNALLING AND PATHOGENIC B CELL CHEMOTAXIS IN PATIENTS WITH IGG4-RELATED DISEASE
T. Guy, H. Liu, V. Mahajan, C. Perugino, Z. S. Wallace, S. Quinn, M. Matijevic, A. Poma, D. Zach, J. H. Stone, S. Pillai

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1132-1133; DOI: 10.1136/annrheumdis-2024-eular.3179
POS0899 FIRST-IN-HUMAN SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS DATA WITH MK-6194, A MODIFIED FORM OF INTERLEUKIN-2, DESIGNED TO SELECTIVELY ACTIVATE REGULATORY T-CELLS – SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE TRIALS
J. Scheid, A. Cunningham-Bussel, N. Kim, S. Agarwal, G. Nieddu, J. Cote, L. Lemoine, T. Decaestekar, L. Mendez, E. Paul, L. Love-Gregory, A. V. Contreras, L. Pang, G. Baltus, M. Beaumont, K. Shah, N. Higginson-Scott, K. Kis-Toth, K. Otipoby, J. L. Viney, E. Sicard, S. Rottey, J. S. Sundy, K. Vandyck, T. Laethem, P. Larson, S. Sutradhar, R. Wnek, T. Bueters, E. Lai, A. Stoch, M. Iwamoto, J. Robbins

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1136-1137; DOI: 10.1136/annrheumdis-2024-eular.618
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
G. R. Burmester, S. B. Cohen, A. Deodhar, E. Mysler, A. Rubbert-Roth, Y. Tanaka, K. L. Winthrop, P. Nakasato, D. Coombs, A. Gara, N. Khan, B. Kovacs, S. Meerwein, J. R. Curtis

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1137-1138; DOI: 10.1136/annrheumdis-2024-eular.809
POS0888 PHARMACOKINETICS OF CERTOLIZUMAB PEGOL IN PREGNANCY: RESULTS FROM THE OPEN-LABEL, PHASE 1B CHERISH STUDY
M. E. B. Clowse, R. J. E. M. Dolhain, S. Finzel, F. Förger, C. Glaser, A. Pluma Sanjurjo, L. Shaughnessy, J. Sidhu, J. Greenin, K. Rice, M. Teil

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1145-1146; DOI: 10.1136/annrheumdis-2024-eular.2965
POS0909 A PHASE 1 SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF ZB002, AN ANTI-TNFΑ MAB DESIGNED FOR EXTENDED HALF-LIFE, IN HEALTHY VOLUNTEERS
C. Sellwood, S. Wax, M. Gao, M. Matijevic, M. Yamashita, S. Yu, S. Arora, R. Kirk

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1148; DOI: 10.1136/annrheumdis-2024-eular.3164
POS0891 CONTINUATION VERSUS TEMPORARY INTERRUPTION OF IMMUNOMODULATORY AGENTS DURING INFECTIONS: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL IN 1142 PATIENTS WITH INFLAMMATORY ARTHRITIS
M. Opdam, N. Den Broeder, R. Van Crevel, J. Broen, L. M. Verhoef, A. A. Den Broeder

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1156-1157; DOI: 10.1136/annrheumdis-2024-eular.5332

Main menu

clinical trial

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trial

Pages